Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Dysphagia, Head and Neck Cancer
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
- Trial name
- NCT00503776
- Testing
- exercise intervention, amifostine trihydrate, therapeutic dietary intervention
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
This study will examine the effects of an investigational drug called AT-101 in combination with an FDA approved cancer drug called Docetaxel.
- Trial name
- NCT01285635
- Testing
- AT-101, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Squamous Cell Carcinoma
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
Patients with locally advanced (stage III to stage IVB) poorly differentiated head and neck squamous cell carcinoma (excluding nasopharyngeal carcinoma) who meet the inclusion criteria will have their blood samples collected…
- Trial name
- NCT06100497
- Testing
- Pembrolizumab, Cisplatin, Paclitaxel-albumin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Tongren Hospital
Head and Neck Squamous Cell Carcinoma
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
The primary aim of the phase 1 portion of the trial is to establish the recommended phase 2 dose (RP2D) of tazemetostat in combination with a fixed dose of pembrolizumab in patients with recurrent or metastatic (RM) head and neck…
- Trial name
- NCT04624113
- Testing
- Tazemetostat, Pembrolizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Squamous Cell Carcinoma of Hypopharynx, Squamous Cell Carcinoma of Larynx
Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
Patients undergoing concurrent chemoradiotherapy (CCRT) for head and neck squamous cell carcinoma frequently experience treatment-related toxicities including mucositis, dysphagia, acute kidney injury, pain, constipation…
- Conditions
- Squamous Cell Carcinoma of Hypopharynx, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT07784855
- Testing
- Scheduled IV Hydration, Clinician Assessment-Based IV Hydration
- Where
- 6 sites in United States
- Volunteers
- 180 people
- Sponsor
- West Virginia University
Head and Neck Cancer
S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00100789
- Testing
- gemcitabine, paclitaxel
- Where
- 123 sites in United States
- Volunteers
- 67 people
- Sponsor
- SWOG Cancer Research Network
Esophageal Carcinoma
Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
GLOBOCAN 2020 reported that the global incidence of esophageal cancer climbed to 604,100, accounting for 3.1% of all tumor sites and ranking 7th out of 36 cancers.
- Trial name
- CAR-RMEC (NCT06681285)
- Testing
- Cadonilimab ;Anlotinib
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Hebei Medical University Fourth Hospital
Head and Neck Cancer
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer
- Trial name
- NCT00304278
- Testing
- Erlotinib (Tarceva), Intra-arterial Cisplatin (PLAT), Radiation Therapy (RAD)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Southern Illinois University
Esophagus SCC
Neoadjuvant Immunotherapy to ESCC
Currently, surgery after neoadjuvant chemoradiotherapy is the standard treatment for patients with locally advanced esophageal cancer, but the recurrence rate is high and the 5-year survival rate is low.
- Trial name
- NCT04625543
- Testing
- Sintilimab Injection plus Paclitaxel and Cisplatin, Paclitaxel and Cisplatin
- Where
- China
- Sponsor
- Qilu Hospital of Shandong University
Head and Neck Cancer
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
The purpose of the study is to evaluate Medpulser electroporation (EPT) with bleomycin with regard to local tumor recurrence, disease-free survival, and overall survival rates versus surgery in recurrent or secondary primary…
- Trial name
- NCT00198315
- Testing
- Medpulser electroporation with Bleomycin, Tumor surgical excision
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Inovio Pharmaceuticals
Oropharyngeal Cancer, Squamous Cell Carcinoma to the Head and Neck
A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.
To assess the efficacy of pregabalin in the management of mucositis pain in patients receiving radiotherapy to the head and neck.
- Trial name
- NCT02277548
- Testing
- Lyrica 300 mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Head and Neck Cancer, Non-melanomatous Skin Cancer
Radiation Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy is more effective for head and neck cancer.
- Trial name
- NCT00021125
- Testing
- adjuvant therapy, radiation therapy
- Where
- United Kingdom
- Volunteers
- 460 people
- Sponsor
- Medical Research Council
Head and Neck Squamous Cell Carcinoma
SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of first-line with recombinant anti-EGFR monoclonal antibody（SCT200）and standard chemotherapy in patients with Recurrent and/or Metastatic Head and Neck Squamous…
- Trial name
- NCT03744208
- Testing
- Anti-EGFR monoclonal antibody
- Volunteers
- 30 people
- Sponsor
- Shi Yuankai
Esophageal Cancer, Squamous Cell
Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia
In recent years, endocytoscopy (EC) has undergone rapid development as an advanced endoscopic technique. Characterized by real-time histological imaging and detection capabilities, EC enables visualization of living cells in the…
- Trial name
- NCT06984055
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Changhai Hospital
Squamous Cell Carcinoma of the Head and Neck
SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
This is a retrospective international, multi-center, non-interventional cohort study based on use of data derived from established medical records and secondary analysis of archival tumor samples.
- Trial name
- SUPREME-HN (NCT02543476)
- Where
- 18 sites in United States, Germany and 5 more
- Volunteers
- 412 people
- Sponsor
- AstraZeneca
Esophageal Cancer
Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial
The goal of this clinical research study is to learn how safe and effective proton-beam therapy (PBT) may be in comparison to intensity modulated radiation therapy (IMRT) in combination with chemotherapy in patients with…
- Trial name
- NCT01512589
- Testing
- Proton Beam Therapy (PBT), Intensity Modulated Radiation Therapy (IMRT), Questionnaires
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- M.D. Anderson Cancer Center
Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to look at the efficacy and safety of sintilimab in combination with carboplatin and nab-paclitaxel in patients with oral cavity or oropharyngeal squamous cell carcinoma who are about to undergo…
- Trial name
- OOC-001 (NCT04718415)
- Testing
- sintilimab, paclitaxel, carboplatin, Surgical resection
- Where
- 2 sites in China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Squamous Cell Carcinoma
Feasibility of a Carbohydrate-restricted, High-fat Diet on Head and Neck Squamous Cell Carcinoma Outcomes
This study will test the feasibility of a carbohydrate-restricted, high-fat (CRHF) diet intervention in newly diagnosed head and neck squamous cell carcinoma patients who will receive definitive radiation.
- Trial name
- CRHF (NCT04253808)
- Testing
- Carbohydrate-restricted, high-fat diet, Regular composition diet
- Where
- Palestinian Territories
- Volunteers
- 39 people
- Sponsor
- University of Illinois at Urbana-Champaign
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Head and Neck Cancer, Advanced Cancer
Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)
This study aims to study the kinetics of ctDNA levels after the first dose of immune checkpoint inhibitor in patients with recurrent or metastatic head and neck cancer.
- Conditions
- Head and Neck Cancer, Advanced Cancer, Metastatic Cancer, HNSCC
- Trial name
- NCT04606940
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.